CD74: An emerging opportunity as a therapeutic target in cancer and autoimmune disease

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 3, 2011, Pages 237-251

  Borghese, Federica ^a,b   Clanchy, Felix Il ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Antigen presentation; Cancer; Cathepsin; CD44; CD74; Inflammatory disease; Invariant chain; MIF

Indexed keywords

CATHEPSIN; CATHEPSIN S INHIBITOR; CD74 ANTIGEN; DOXORUBICIN; MACROPHAGE MIGRATION INHIBITION FACTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MILATUZUMAB; RANPIRNASE; RWJ 445380; TETANUS TOXOID; UNCLASSIFIED DRUG; VELTUZUMAB;

ABSENCE OF SIDE EFFECTS; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ANTIGEN STRUCTURE; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; B LYMPHOCYTE; CARCINOGENESIS; CELL MOTILITY; DENDRITIC CELL; HUMAN; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; REVIEW; RHEUMATOID ARTHRITIS; STOMACH CANCER; TETANUS; THYMUS;

ANIMALS; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; AUTOIMMUNE DISEASES; CATHEPSINS; DRUG DELIVERY SYSTEMS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INFLAMMATION; NEOPLASMS;

EID: 79951605495     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2011.550879     Document Type: Review

References (155)

1. Strubin M, Long EO, Mach B. Two forms of the Ia antigen-associated invariant chain result from alternative initiations at two in-phase AUGs. Cell 1986;47(4):619-25 (Pubitemid 17215351)
2. Schutze MP, Peterson PA, Jackson MR. An N-terminal double-arginine motif maintains type II membrane proteins in the endoplasmic reticulum. EMBO J 1994;13(7):1696-705 (Pubitemid 24114722)
3. Strubin M, Berte C, Mach B. Alternative splicing and alternative initiation of translation explain the four forms of the Ia antigen-associated invariant chain. EMBO J 1986;5(13):3483-8.
4. Kampgen E, Koch N, Koch F, et al. Class II major histocompatibility complex molecules of murine dendritic cells: synthesis, sialylation of invariant chain, and antigen processing capacity are down-regulated upon culture. Proc Natl Acad Sci USA 1991;88(8):3014-18 (Pubitemid 21916550)
5. Romagnoli P, Germain RN. Inhibition of invariant chain (Ii)-calnexin interaction results in enhanced degradation of Ii but does not prevent the assembly of alpha beta Ii complexes. J Exp Med 1995;182(6):2027-36
6. Bijlmakers MJ, Benaroch P, Ploegh HL. Mapping functional regions in the lumenal domain of the class II-associated invariant chain. J Exp Med 1994;180(2):623-9
7. Ou WJ, Cameron PH, Thomas DY, et al. Association of folding intermediates of glycoproteins with calnexin during protein maturation. Nature 1993;364(6440):771-6 (Pubitemid 23261757)
8. Jasanoff A, Wagner G, Wiley DC. Structure of a trimeric domain of the MHC class II-associated chaperonin and targeting protein Ii. EMBO J 1998;17(23):6812-18 (Pubitemid 28550274)
9. Ashman JB, Miller J. A role for the transmembrane domain in the trimerization of the MHC class II-associated invariant chain. J Immunol 1999;163(5):2704-12 (Pubitemid 29399196)
10. Roche PA, Marks MS, Cresswell P. Formation of a nine-subunit complex by HLA class II glycoproteins and the invariant chain. Nature 1991;354(6352):392-4 (Pubitemid 21896847)
11. Hofmann MW, Honing S, Rodionov D, et al. The leucine-based sorting motifs in the cytoplasmic domain of the invariant chain are recognized by the clathrin adaptors AP1 and AP2 and their medium chains. J Biol Chem 1999;274(51):36153-8
12. Motta A, Bremnes B, Morelli MA, et al. Structure-activity relationship of the leucine-based sorting motifs in the cytosolic tail of the major histocompatibility complex-associated invariant chain. J Biol Chem 1995;270(45):27165-71
13. Zhong G, Romagnoli P, Germain RN. Related leucine-based cytoplasmic targeting signals in invariant chain andmajor histocompatibility complex class II molecules control endocytic presentation of distinct determinants in a single protein. J Exp Med 1997;185(3):429-38 (Pubitemid 27078361)
14. Simonsen A, Pedersen KW, Nordeng TW, et al. Polarized transport of MHC class II molecules in Madin-Darby canine kidney cells is directed by a leucine-based signal in the cytoplasmic tail of the beta-chain. J Immunol 1999;163(5):2540-8
15. Pinet V, Vergelli M, Martin R, et al. Antigen presentation mediated by recycling of surface HLA-DR molecules. Nature 1995;375(6532):603-6
16. Roche PA, Teletski CL, Stang E, et al. Cell surface HLA-DR-invariant chain complexes are targeted to endosomes by rapid internalization. Proc Natl Acad Sci USA 1993;90(18):8581-5 (Pubitemid 23277713)
17. Arneson LS, Miller J. The chondroitin sulfate form of invariant chain trimerizes with conventional invariant chain and these complexes are rapidly transported from the trans-Golgi network to the cell surface. Biochem J 2007;406(1):97-103 (Pubitemid 47264739)
18. Sant AJ, Schwartz BD, Cullen SE. Cellular distribution of the Ia-associated chondroitin sulfate proteoglycan. J Immunol 1985;135(1):408-15 (Pubitemid 15011461)
19. Sant AJ, Cullen SE, Giacoletto KS, et al. Invariant chain is the core protein of the Ia-associated chondroitin sulfate proteoglycan. J Exp Med 1985;162(6):1916-34 (Pubitemid 16149686)
20. Ericson ML, Sundstrom M, Sansom DM, et al. Mutually exclusive binding of peptide and invariant chain to major histocompatibility complex class II antigens. J Biol Chem 1994;269(42):26531-8.
21. Park SJ, Sadegh-Nasseri S, Wiley DC. Invariant cha made in Escherichia coli has an exposed N-terminal segment that blocks antigen binding to HLA-DR1 and a trimeric C-terminal segment that binds empty HLA-DR1. Proc Natl Acad Sci USA 1995;92(24):11289-93
22. Kropshofer H, Vogt AB, Stern LJ, et al. Self-release of CLIP in peptide loading of HLA-DR molecules. Science 1995;270(5240):1357-9
23. Thayer WP, Ignatowicz L, Weber DA, et al. Class II-associated invariant chain peptide-independent binding of invariant chain to class II MHC molecules. J Immunol 1999;162(3):1502-9 (Pubitemid 29307023)
24. Castellino F, Han R, Germain RN. The transmembrane segment of invariant chain mediates binding to MHC class II molecules in a CLIP-independent manner. Eur J Immunol 2001;31(3):841-50 (Pubitemid 32237120)
25. Riese RJ, Wolf PR, Bromme D, et al. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity 1996;4(4):357-66 (Pubitemid 26174051)
26. Roche PA, Cresswell P. Proteolysis of the class II-associated invariant chain generates a peptide binding site in intracellular HLA-DR molecules. Proc Natl Acad Sci USA 1991;88(8):3150-4 (Pubitemid 21916577)
27. Landsverk OJ, Bakke O, Gregers TF. MHC II and the endocytic pathway: regulation by invariant chain. Scand J Immunol 2009;70(3):184-93
28. Rocha N, Neefjes J. MHC class II molecules on the move for successful antigen presentation. EMBO J 2008;27(1):1-5
29. Manoury B, Mazzeo D, Li DN, et al. Asparagine endopeptidase can initiate the removal of the MHC class II invariant chain chaperone. Immunity 2003;18(4):489-98 (Pubitemid 36513631)
30. Nakagawa T, Roth W, Wong P, et al. Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus. Science 1998;280(5362):450- 3. (Pubitemid 28208170)
31. Koch N, Lauer W, Habicht J, et al. Primary structure of the gene for the murine Ia antigen-associated invariant chains (Ii). An alternatively spliced exon encodes a cysteine-rich domain highly homologous to a repetitive sequence of thyroglobulin. EMBO J 1987;6(6):1677-83
32. Mihelic M, Dobersek A, Guncar G, et al. Inhibitory fragment from the p41 form of invariant chain can regulate activity of cysteine cathepsins in antigen presentation. J Biol Chem 2008;283(21):14453-60.
33. Turk D, Guncar G, Turk V. The p41 fragment story. IUBMB Life 1999;48(1):7-12 (Pubitemid 29512978)
34. Carmona E, Dufour E, Plouffe C, et al. Potency and selectivity of the cathepsin L propeptide as an inhibitor of cysteine proteases. Biochemistry 1996;35(25):8149-57 (Pubitemid 26234914)
35. Coulombe R, Grochulski P, Sivaraman J, et al. Structure of human procathepsin L reveals the molecular basis of inhibition by the prosegment. EMBO J 1996;15(20):5492-503 (Pubitemid 26385609)
36. Jerala R, Zerovnik E, Kidric J, et al. pH-induced conformational transitions of the propeptide of human cathepsin L. A role for a molten globule state in zymogen activation. J Biol Chem 1998;273(19):11498-504 (Pubitemid 28272044)
37. Mason RW, Massey SD. Surface activation of pro-cathepsin L. Biochem Biophys Res Commun 1992;189(3):1659-66 (Pubitemid 23041353)
38. Lennon-Dumenil AM, Roberts RA, Valentijn K, et al. The p41 isoform of invariant chain is a chaperone for cathepsin L. EMBO J 2001;20(15):4055-64 (Pubitemid 32751822)
39. Ogrinc T, Dolenc I, Ritonja A, et al. Purification of the complex of cathepsin L and the MHC class II-associated invariant chain fragment from human kidney. FEBS Lett 1993;336(3):555-9 (Pubitemid 24037018)
40. Fiebiger E, Maehr R, Villadangos J, et al. Invariant chain controls the activity of extracellular cathepsin L. J Exp Med 2002;196(9):1263-9. (Pubitemid 35304191)
41. Shi GP, Villadangos JA, Dranoff G, et al. Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity 1999;10(2):197-206 (Pubitemid 29115625)
42. Nakagawa TY, Brissette WH, Lira PD, et al. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity 1999;10(2):207-17 (Pubitemid 29115626)
43. Yang H, Kala M, Scott BG, et al. Cathepsin S is required for murine autoimmune myasthenia gravis pathogenesis. J Immunol 2005;174(3):1729-37
44. Starlets D, Gore Y, Binsky I, et al. Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood 2006;107(12):4807-16. (Pubitemid 43882632)
45. Becker-Herman S, Arie G, Medvedovsky H, et al. CD74 is a member of the regulated intramembraneproteolysis-processed protein family. Mol Biol Cell 2005;16(11):5061-9. (Pubitemid 41566819)
46. Ehrmann M, Clausen T. Proteolysis as a regulatory mechanism. Annu Rev Genet 2004;38:709-24 (Pubitemid 40013742)
47. Brown MS, Ye J, Rawson RB, et al. Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell 2000;100(4):391-8
48. Leng L, Metz CN, Fang Y, et al. MIF signal transduction initiated by binding to CD74. J Exp Med 2003;197(11):1467-76 (Pubitemid 36686708)
49. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003;3(10):791-800 (Pubitemid 37328657)
50. Anderson HA, Roche PA.Phosphorylation regulates the delivery of MHC class II invariant chain complexes to antigen processing compartments. J Immunol 1998;160(10):4850-8 (Pubitemid 28215319)
51. Shi X, Leng L, Wang T, et al. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 2006;25(4):595-606 (Pubitemid 44529040)
52. Naujokas MF, Morin M, Anderson MS, et al. The chondroitin sulfate form of invariant chain can enhance stimulation of T cell responses through interaction with CD44. Cell 1993;74(2):257-68 (Pubitemid 23221702)
53. Gore Y, Starlets D, Maharshak N, et al. Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. J Biol Chem 2008;283(5):2784-92
54. Matza D, Wolstein O, Dikstein R, et al. Invariant chain induces B cell maturation by activating a TAF(II)105-NF-kappaBdependenttranscription program. J Biol Chem 2001;276(29):27203-6.
55. Weber C, Kraemer S, Drechsler M, et al. Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment. Proc Natl Acad Sci USA 2008;105(42):16278-83
56. Bernhagen J, Krohn R, Lue H, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 2007;13(5):587-96 (Pubitemid 46828480)
57. Cho Y, Crichlow GV, Vermeire JJ, et al. Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast. Proc Natl Acad Sci USA 2010;107(25):11313-18
58. Matza D, Lantner F, Bogoch Y, et al. Invariant chain induces B cell maturation in a process that is independent of its chaperonic activity. Proc Natl Acad Sci USA 2002;99(5):3018-23 (Pubitemid 34240578)
59. Faure-Andre G, Vargas P, Yuseff MI, et al. Regulation of dendritic cell migration by CD74, the MHC class II-associated invariant chain. Science 2008;322(5908):1705-10.
60. Vascotto F, Lankar D, Faure-Andre G, et al. The actin-based motor protein myosin II regulates MHC class II trafficking and BCR-driven antigen presentation. J Cell Biol 2007;176(7):1007-19 (Pubitemid 46506973)
61. Badve S, Deshpande C, Hua Z, et al. Expression of invariant chain (CD 74) and major histocompatibility complex (MHC) class II antigens in the human fetus. J Histochem Cytochem 2002;50(4):473-82 (Pubitemid 34250586)
62. Wright RJ, Bikoff EK, Stockinger B. The Ii41 isoform of invariant chain mediates both positive and negative selection events in T-cell receptor transgenic mice. Immunology 1998;95(3):309-13 (Pubitemid 28505684)
63. Wong P, Rudensky AY. Phenotype and function of CD4+ T cells in mice lacking invariant chain. J Immunol 1996;156(6):2133-42 (Pubitemid 26087443)
64. Kasai M, Kropshofer H, Vogt AB, et al. CLIP-derived self peptides bound to MHC class II molecules of medullary thymic epithelial cells differ from those of cortical thymic epithelial cells in their diversity, length, and C-terminal processing. Eur J Immunol 2000;30(12):3542-51 (Pubitemid 32005226)
65. Arudchelvan Y, Nishimura Y, Tokuda N, et al. Differential expression of MHC class II antigens and cathepsin L by subtypes of cortical epithelial cells in the rat thymus: an immunoelectron microscopic study. J Electron Microsc (Tokyo) 2002;51(3):173-81 (Pubitemid 34689127)
66. Tolosa E, Li W, Yasuda Y, et al. Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis. J Clin Invest 2003;112(4):517-26 (Pubitemid 38056336)
67. Honey K, Nakagawa T, Peters C, et al. Cathepsin L regulates CD4+ T cell selection independently of its effect on invariant chain: a role in the generation of positively selecting peptide ligands. J Exp Med 2002;195(10):1349-58 (Pubitemid 34564336)
68. Oliver J, Marquez A, Gomez-Garcia M, et al. Association of the macrophage migration inhibitory factor gene polymorphisms with inflammatory bowel disease. Gut 2007;56(1):150-1 (Pubitemid 46044902)
69. Lehmann LE, Book M, Hartmann W, et al. A MIF haplotype is associated with the outcome of patients with severe sepsis: a case control study. J Transl Med 2009;7:100
70. Nunez C, Rueda B, Martinez A, et al. Involvement of macrophage migration inhibitory factor gene in celiac disease susceptibility. Genes Immun 2007;8(2):168-70 (Pubitemid 46390916)
71. Vazquez A, Grochola LF, Bond EE, et al. Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survival. Cancer Res 2010;70(1):172-80
72. Holoshitz J. The rheumatoid arthritis HLA-DRB1 shared epitope. Curr Opin Rheumatol 2010;22(3):293-8
73. Battegay M, Bachmann MF, Burhkart C, et al. Antiviral immune responses of mice lacking MHC class II or its associated invariant chain. Cell Immunol 1996;167(1):115-21 (Pubitemid 26048853)
74. Ye Q, Finn PW, Sweeney R, et al. MHC class II-associated invariant chain isoforms regulate pulmonary immune responses. J Immunol 2003;170(3):1473-80 (Pubitemid 36139517)
75. Martin-Ventura JL, Madrigal-Matute J, Munoz-Garcia B, et al. Increased CD74 expression in human atherosclerotic plaques: contribution to inflammatory responses in vascular cells. Cardiovasc Res 2009;83(3):586-94
76. Sun J, Hartvigsen K, Chou MY, et al. Deficiency of antigen-presenting cell invariant chain reduces atherosclerosis in mice. Circulation 2010;122(8):808-20
77. Schober A, Bernhagen J, Weber C. Chemokine-like functions of MIF in atherosclerosis. J Mol Med 2008;86(7):761-70
78. Samokhin AO, Lythgo PA, Gauthier JY, et al. Pharmacological inhibition of cathepsin S decreases atherosclerotic lesions in Apoe-/- mice. J Cardiovasc Pharmacol 2010;56(1):98-105
79. Lapter S, Ben-David H, Sharabi A, et al. A role for the B-cell CD74/macrophage migration inhibitory factor pathway in the immunomodulation of systemic lupus erythematosus by a therapeutic tolerogenic peptide. Immunology 2011;132(1):87-95
80. Yoshiyama Y, Arai K, Oki T, et al. Expression of invariant chain and pro-cathepsin L in Alzheimer's brain. Neurosci Lett 2000;290(2):125-8 (Pubitemid 30628357)
81. Bryan KJ, Zhu X, Harris PL, et al. Expression of CD74 is increased in neurofibrillary tangles in Alzheimer's disease. Mol Neurodegener 2008;3:13
82. Matsuda S, Matsuda Y, D'Adamio L. CD74 interacts with APP and suppresses the production of Abeta. Mol Neurodegener 2009;4:41
83. Teo BH, Wong SH. MHC class II-associated invariant chain (Ii) modulates dendritic cells-derived microvesicles (DCMV)-mediated activation of microglia. Biochem Biophys Res Commun 2010;400(4):673-8
84. Mellanby RJ, Koonce CH, Monti A, et al. Loss of invariant chain protects nonobese diabetic mice against type 1 diabetes. J Immunol 2006;177(11):7588-98 (Pubitemid 44846273)
85. Beswick EJ, Das S, Pinchuk IV, et al. Helicobacter pylori-induced IL-8 production by gastric epithelial cells up-regulates CD74 expression. J Immunol 2005;175(1):171-6 (Pubitemid 40884314)
86. Beswick EJ, Pinchuk IV, Minch K, et al. The Helicobacter pylori urease B subunit binds to CD74 on gastric epithelial cells and induces NF-kappaB activation and interleukin-8 production. Infect Immun 2006;74(2):1148-55. This is the first paper that to show CD74 as a receptor for a non-viral pathogen. (Pubitemid 43185553)
87. Wong BL, Zhu SL, Huang XR, et al. Essential role for macrophage migration inhibitory factor in gastritis induced by Helicobacter pylori. Am J Pathol 2009;174(4):1319-28
88. Dambacher J, Staudinger T, Seiderer J, et al. Macrophage migration inhibitory factor (MIF) -173G/C promoter polymorphism influences upper gastrointestinal tract involvement and disease activity in patients with Crohn's disease. Inflamm Bowel Dis 2007;13(1):71-82 (Pubitemid 46080012)
89. Murakami H, Akbar SM, Matsui H, et al. Macrophage migration inhibitory factor in the sera and at the colonic mucosa in patients with ulcerative colitis: clinical implications and pathogenic significance. Eur J Clin Invest 2001;31(4):337-43 (Pubitemid 32328535)
90. Murakami H, Akbar SM, Matsui H, et al. Macrophage migration inhibitory factor activates antigen-presenting dendritic cells and induces inflammatory cytokines in ulcerative colitis. Clin Exp Immunol 2002;128(3):504-10 (Pubitemid 34639313)
91. Ishiguro Y, Ohkawara T, Sakuraba H, et al. Macrophage migration inhibitory factor has a proinflammatory activity via the p38 pathway in glucocorticoid-resistant ulcerative colitis. Clin Immunol 2006;120(3):335-41 (Pubitemid 44175900)
92. O'Keeffe J, Lynch S, Whelan A, et al. Flow cytometric measurement of intracellular migration inhibition factor and tumour necrosis factor alpha in the mucosa of patients with celiac disease. Clin Exp Immunol 2001;125(3):376-82 (Pubitemid 34155433)
93. de Jong YP, Abadia-Molina AC, Satoskar AR, et al. Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol 2001;2(11):1061-6 (Pubitemid 33069502)
94. Lue H, Kapurniotu A, Fingerle-Rowson G, et al. Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal 2006;18(5):688-703 (Pubitemid 43113299)
95. Beswick EJ, Reyes VE. CD74 in antigen presentation, inflammation, and cancers of the gastrointestinal tract. World J Gastroenterol 2009;15(23):2855-61. This review details the involvement of CD74 in gastrointestinal disease with particular regard to mechanisms of carcinogenesis.
96. Aihara M, Tsuchimoto D, Takizawa H, et al. Mechanisms involved in Helicobacter pylori-induced interleukin-8 production by a gastric cancer cell line, MKN45. Infect Immun 1997;65(8):3218-24 (Pubitemid 27342402)
97. Hatakeyama M. Helicobacter pylori causes gastric cancer by hijacking cell growth signaling. Discov Med 2004;4(24):476-81
98. Lee CW, Rickman B, Rogers AB, et al. Helicobacter pylori eradication prevents progression of gastric cancer in hypergastrinemic INS-GAS mice. Cancer Res 2008;68(9):3540-8
99. Nakamura S, Yao T, Aoyagi K, et al.Helicobacter pylori and primary gastric lymphoma. A histopathologic and immunohistochemical analysis of 237 patients. Cancer 1997;79(1):3-11 (Pubitemid 26425501)
100. Romo-Gonzalez C, Salama NR, Burgeno-Ferreira J, et al. Differences in genome content among Helicobacter pylori isolates from patients with gastritis, duodenal ulcer, or gastric cancer reveal novel disease-associated genes. Infect Immun 2009;77(5):2201-11
101. Rudi J, Kolb C, Maiwald M, et al. Diversity of Helicobacter pylori vacA and cagA genes and relationship to VacA and CagA protein expression, cytotoxin production, and associated diseases. J Clin Microbiol 1998;36(4):944-8 (Pubitemid 28146273)
102. Targa AC, Cesar AC, Cury PM, et al. Apoptosis in different gastric lesions and gastric cancer: relationship with Helicobacter pylori, overexpression of p53 and aneuploidy. Genet Mol Res 2007;6(3):554-65 (Pubitemid 350096890)
103. Binsky I, Haran M, Starlets D, et al. IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc Natl Acad Sci USA 2007;104(33):13408-13 (Pubitemid 47293958)
104. Datta MW, Shahsafaei A, Nadler LM, et al. Expression of MHC class II-associated invariant chain (Ii;CD74) in thymic epithelial neoplasms. Appl Immunohistochem Mol Morphol 2000;8(3):210-15
105. McClelland M, Zhao L, Carskadon S, et al. Expression of CD74, the receptor for macrophage migration inhibitory factor, in non-small cell lung cancer. Am J Pathol 2009;174(2):638-46
106. Meyer-Siegler KL, Iczkowski KA, Leng L, et al. Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. J Immunol 2006;177(12):8730-9 (Pubitemid 44893839)
107. Meyer-Siegler KL, Iczkowski KA, Vera PL. Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer. BMC Cancer 2005;5:73
108. Nagata S, Jin YF, Yoshizato K, et al. CD74 is a novel prognostic factor for patients with pancreatic cancer receiving multimodal therapy. Ann Surg Oncol 2009;16(9):2531-8
109. Verjans E, Noetzel E, Bektas N, et al. Dual role of macrophage migration inhibitory factor (MIF) in human breast cancer. BMC Cancer 2009;9:230
110. Cuthbert RJ, Wilson JM, Scott N, et al. Differential CD74 (major histocompatibility complex Class II invariant chain) expression in mouse and human intestinal adenomas. Eur J Cancer 2009;45(9):1654-63
111. Burton JD, Ely S, Reddy PK, et al. CD74 is expressed by multiple myeloma and is a promising target for therapy. Clin Cancer Res 2004;10(19):6606-11 (Pubitemid 39346557)
112. Stein R, Qu Z, Cardillo TM, et al. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood 2004;104(12):3705-11 This paper highlights the potential of anti-CD74 antibodies for B-cell neoplasia compared with anti-CD20. (Pubitemid 39564448)
113. Koch N, Harris AW. Differential expression of the invariant chain in mouse tumor cells: relationship to B lymphoid development. J Immunol 1984;132(1):12-5 (Pubitemid 14213822)
114. Jones PP, Murphy DB, Hewgill D, et al. Detection of a common polypeptide chain in I-A and I-E sub-region immunoprecipitates. Mol Immunol 1979;16(1):51-60 (Pubitemid 9169395)
115. Blum JS, Cresswell P. Role for intracellular proteases in the processing and transport of class II HLA antigens. Proc Natl Acad Sci USA 1988;85(11):3975-9
116. Shih NY, Floyd-Smith G. Invariant chain (CD74) gene regulation: enhanced expression associated with activation of protein kinase C delta in a murine B lymphoma cell line. Mol Immunol 1995;32(9):643-50
117. Shih NY, Soesilo I, Floyd-Smith G. Stabilization of invariant chain mRNA by 12-O-tetradecanoylphorbol-13-acetate is blocked by IFN-gamma in a murine B lymphoma cell line. J Interferon Cytokine Res 1997;17(12):747-55 (Pubitemid 28027987)
118. Binsky I, Lantner F, Grabovsky V, et al. TAp63 regulates VLA-4 expression and chronic lymphocytic leukemia cell migration to the bone marrow in a CD74-dependent manner. J Immunol; 184(9):4761-9
119. Pyrz M, Wang B, Wabl M, et al. A retroviral mutagenesis screen identifies Cd74 as a common insertion site in murine B-lymphomas and reveals the existence of a novel IFNgamma-inducible Cd74 isoform. Mol Cancer 2010;9:86
120. Stein R, Mattes MJ, Cardillo TM, et al. CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res 2007; 13(18 Pt 2):5556s-63s (Pubitemid 47510387)
121. Berkova Z, Tao RH, Samaniego F. Milatuzumab - a promising new immunotherapeutic agent. Expert Opin Investig Drugs 2010;19(1):141-9
122. Miles RR, Cairo MS, Satwani P, et al. Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas: a children's oncology group report. Br J Haematol 2007;138(4):506-12 (Pubitemid 47063039)
123. Hansen HJ, Ong GL, Diril H, et al. Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas. Biochem J 1996;320(Pt 1):293-300
124. Liu YH, Lin CY, Lin WC, et al. Up-regulation of vascular endothelial growth factor-D expression in clear cell renal cell carcinoma by CD74: a critical role in cancer cell tumorigenesis. J Immunol 2008;181(9):6584-94
125. Conroy H, Mawhinney L, Donnelly SC. Inflammation and cancer: macrophage migration inhibitory factor (MIF)-the potential missing link. QJM 2010;103(11):831-6
126. Mark T, Martin P, Leonard JP, et al. Milatuzumab: a promising new agent for the treatment of lymphoid malignancies. Expert Opin Investig Drugs 2009;18(1):99-104
127. Griffiths GL, Mattes MJ, Stein R, et al. Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate. Clin Cancer Res 2003;9(17):6567-71 (Pubitemid 38031846)
128. Lundberg BB, Griffiths G, Hansen HJ. Cellular association and cytotoxicity of anti-CD74-targeted lipid drug-carriers in B lymphoma cells. J Control Release 2004;94(1):155-61 (Pubitemid 37542385)
129. Ochakovskaya R, Osorio L, Goldenberg DM, et al. Therapy of disseminated B-cell lymphoma xenografts in severe combined immunodeficient mice with an anti-CD74 antibody conjugated with (111)indium, (67)gallium, or (90) yttrium. Clin Cancer Res 2001;7(6):1505-10 (Pubitemid 32708612)
130. Sapra P, Stein R, Pickett J, et al. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin Cancer Res 2005;11(14):5257-64 (Pubitemid 41003714)
131. Chang CH, Sapra P, Vanama SS, et al. Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin. Blood 2005;106(13):4308-14 (Pubitemid 41775941)
132. Kaufman J, Niesvizky R, Stadtmauer EA, et al. First Trial of Humanized Anti-CD74 Monoclonal Antibody (MAb), Milatuzumab, in Multiple Myeloma. ASH Annual Meeting Abstracts 2008;112(11):3697 [abstract]
133. Kaufman JL, Niesvizky R, Stadtmauer EA, et al. Dose-escalation trial of milatuzumab (humanized anti-CD74 monoclonal antibody) in multiple myeloma. J Clin Oncol (Meeting Abstracts) 2009;27(15S):8593 [abstract]
134. Kawasaki A, Hoshino K, Osaki R, et al. Effect of ibudilast: a novel antiasthmatic agent, on airway hypersensitivity in bronchial asthma. J Asthma 1992;29(4):245-52
135. Kishi Y, Ohta S, Kasuya N, et al. Ibudilast: a non-selective PDE inhibitor with multiple actions on blood cells and the vascular wall. Cardiovasc Drug Rev 2001;19(3):215-25 (Pubitemid 34019905)
136. Cho Y, Crichlow GV, Vermeire JJ, et al. Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast. Proc Natl Acad Sci USA 2010;107(25):11313-18
137. Schwartz V, Lue H, Kraemer S, et al. A functional heteromeric MIF receptor formed by CD74 and CXCR4. FEBS Lett 2009;583(17):2749-57
138. Winner M, Meier J, Zierow S, et al. A novel, macrophage migration inhibitory factor suicide substrate inhibits motility and growth of lung cancer cells. Cancer Res 2008;68(18):7253-7
139. Hare AA, Leng L, Gandavadi S, et al. Optimization of N-benzyl-benzoxazol- 2- ones as receptor antagonists of macrophage migration inhibitory factor (MIF). Bioorg Med Chem Lett 2010;20(19):5811-14
140. Ouertatani-Sakouhi H, El-Turk F, Fauvet B, et al. Identification and characterization of novel classes of macrophage migration inhibitory factor (MIF) inhibitors with distinct mechanisms of action. J Biol Chem 2010;285(34):26581-98
141. Podolin PL, Bolognese BJ, Carpenter DC, et al. Inhibition of invariant chain processing, antigen-induced proliferative responses, and the development of collagen-induced arthritis and experimental autoimmune encephalomyelitis by a small molecule cysteine protease inhibitor. J Immunol 2008;180(12):7989-8003
142. Saegusa K, Ishimaru N, Yanagi K, et al. Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. J Clin Invest 2002;110(3):361-9 (Pubitemid 34847968)
143. Riese RJ, Mitchell RN, Villadangos JA, et al. Cathepsin S activity regulates antigen presentation and immunity. J Clin Invest 1998;101(11):2351-63 (Pubitemid 28270429)
144. Wu S, Gorski J. The MHC class II-associated invariant chain-derived peptide clip binds to the peptide-binding groove of class II molecules.Mol Immunol 1996;33(4-5):371-7 (Pubitemid 26191481)
145. Ferrari G, Knight AM, Watts C, et al.Distinct intracellular compartments involved in invariant chain degradation and antigenic peptide loading of major histocompatibility complex (MHC) class II molecules. J Cell Biol 1997;139(6):1433-46 (Pubitemid 28013664)
146. Fujii S, Senju S, Chen YZ, et al. The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells. Hum Immunol 1998;59(10):607-14 (Pubitemid 28436461)
147. Sponaas A, Carstens C, Koch N. C-terminal extension of the MHC class II-associated invariant chain by an antigenic sequence triggers activation of naive T cells. Gene Ther 1999;6(11):1826-34 (Pubitemid 29531278)
148. Barton GM, Rudensky AY. An altered invariant chain protein with an antigenic peptide in place of CLIP forms SDS-stable complexes with class IIalphabeta dimers and facilitates highly fficient peptide loading. Int Immunol 1998;10(8):1159-65 (Pubitemid 28362690)
149. Koch N, van Driel IR, Gleeson PA. Hijacking a chaperone: manipulation of the MHC class II presentation pathway. Immunol Today 2000;21(11):546-50
150. Bischof F, Wienhold W, Wirblich C, et al. Specific treatment of autoimmunity with recombinant invariant chains in which CLIP is replaced by self-epitopes. Proc Natl Acad Sci USA 2001;98(21):12168-73. This study was the first to use CLIP-substituted Ii proteins to induce and suppress disease in a murine model of MS. (Pubitemid 32959845)
151. Gjertsson I, Laurie KL, Devitt J, et al. Tolerance induction using lentiviral gene delivery delays onset and severity of collagen II arthritis. Mol Ther 2009;17(4):632-40
152. Sorensen MR, Holst PJ, Pircher H, et al. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control. Eur J Immunol 2009;39(10):2725-36
153. Humphreys RE, Adams S, Koldzic G, et al. Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide. Vaccine 2000;18(24):2693-7 (Pubitemid 30211577)
154. Perez SA, Kallinteris NL, Bisias S, et al. Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer. Clin Cancer Res 2010;16(13):3495-506
155. Ghosh P, Amaya M, Mellins E, et al. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 1995;378(6556):457-62